Terms: = Bone cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
91 results:
1. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML.
Bauer M; Jäkel N; Wilfer A; Haak A; Eszlinger M; Kelemen K; Haemmerle M; Al-Ali HK; Seliger B; Wickenhauser C
Oncoimmunology; 2024; 13(1):2323212. PubMed ID: 38481730
[TBL] [Abstract] [Full Text] [Related]
3. The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma Treatment
Higgins TA; Patton DJ; Shimko-Lofano IM; Eller TL; Molinari R; Sandey M; Ismail A; Smith BF; Agarwal P
Cells; 2024 Feb; 13(4):. PubMed ID: 38391964
[TBL] [Abstract] [Full Text] [Related]
4. Frequent expression of pd-l1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
[TBL] [Abstract] [Full Text] [Related]
5. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
6. The Association of Immune Cell Infiltration with Metastasis Location in De Novo Metastatic Triple Negative Breast cancer: A Multicenter Cross-Sectional Study in Indonesia.
Tenggara JB; Rachman A; Prihartono J; Lisnawati L; Panigoro SS; Heriyanto DS; Steven R; Tandarto K; Juanputra S; Sudoyo AW
Acta Med Indones; 2023 Oct; 55(4):376-384. PubMed ID: 38213050
[TBL] [Abstract] [Full Text] [Related]
7. PROGNOSTIC IMPLICATIONS OF pd-l1 EXPRESSION AND LOSS OF PTEN IN PATIENTS WITH RHABDOMYOSARCOMA, EWING'S SARCOMA AND OSTEOSARCOMA.
Abd Elmoneim HM; Huwait HF; Nafady-Hego H; Mohamed FA
Exp Oncol; 2023 Dec; 45(3):337-350. PubMed ID: 38186021
[TBL] [Abstract] [Full Text] [Related]
8. Imaging diagnosis and efficacy monitoring by [
He H; Qi X; Fu H; Xu J; Zheng Q; Chen L; Zhang Y; Hua H; Xu W; Xu Z; Chen X; You Q; Lin J; Huang G; Mao Y; Yu C
Theranostics; 2024; 14(1):392-405. PubMed ID: 38164149
[No Abstract] [Full Text] [Related]
9. pd-l1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast cancers and Its Clinicopathological Significance.
Han EK; Woo JW; Suh KJ; Kim SH; Kim JH; Park SY
Cancer Res Treat; 2024 Apr; 56(2):557-566. PubMed ID: 38097920
[TBL] [Abstract] [Full Text] [Related]
10. LOXL4 Shuttled by Tumor Cells-derived Extracellular Vesicles Promotes Immune Escape in Hepatocellular Carcinoma by Activating the STAT1/pd-l1 Axis.
Zhao L; Pei R; Ding Y; Su Z; Li D; Zhu S; Xu L; Zhao H; Zhou W
J Immunother; 2024 Feb-Mar 01; 47(2):64-76. PubMed ID: 38047403
[TBL] [Abstract] [Full Text] [Related]
11. Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer.
Goktas Aydin S; Bilici A; Calis E; Kutlu Y; Hamdard J; Muglu H; Fatih Olmez O; Karci E; Acikgoz O
Int Immunopharmacol; 2023 Nov; 124(Pt B):110947. PubMed ID: 37742369
[TBL] [Abstract] [Full Text] [Related]
12. 18 F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy.
Feng Y; Wang P; Chen Y; Dai W
Nucl Med Commun; 2023 Oct; 44(10):900-909. PubMed ID: 37503694
[TBL] [Abstract] [Full Text] [Related]
13. Neoadjuvant PD-1/pd-l1 axis blockade for patients with head and neck squamous cell carcinoma.
Huang S; Xiong C; Tan K
Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
[TBL] [Abstract] [Full Text] [Related]
14. E-cadherin expression in the tumor microenvironment of advanced epidermal growth factor receptor-mutant lung adenocarcinoma and the association with prognosis.
Chang YP; Huang GK; Chen YC; Huang KT; Chen YM; Lin CY; Huang CC; Lin MC; Wang CC
BMC Cancer; 2023 Jun; 23(1):569. PubMed ID: 37340370
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathological Features and prognosis of Lung Adenocarcinoma Patients With K-RAS Gene Mutation.
Sun D; Liu Y; Li P; Yang P; Yu G
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):406-413. PubMed ID: 37338109
[TBL] [Abstract] [Full Text] [Related]
16. Construction and validation of an oxidative-stress-related risk model for predicting the prognosis of osteosarcoma.
Wang H; Li J; Li X
Aging (Albany NY); 2023 Jun; 15(11):4820-4843. PubMed ID: 37285835
[TBL] [Abstract] [Full Text] [Related]
17. BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma.
Han Y; Pan Q; Guo Z; Du Y; Zhang Y; Liu Y; Zhao J; Xu J; Yang J; Ouyang D; Tang Y; Wang Q; Li Y; He J; Yang M; Chen H; Yang C; Yang X; You J; Chen Y; Ren M; Zhu Y; Xia J; Xiang T
Clin Transl Med; 2023 May; 13(5):e1247. PubMed ID: 37132170
[TBL] [Abstract] [Full Text] [Related]
18. Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type.
Dalens L; Lecuelle J; Favier L; Fraisse C; Lagrange A; Kaderbhai C; Boidot R; Chevrier S; Mananet H; Derangère V; Truntzer C; Ghiringhelli F
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108755
[TBL] [Abstract] [Full Text] [Related]
19. An Immunohistochemical Study of Breast cancer Brain Metastases: The Role of CD44 and AKT in the prognosis.
Martins Gama J; Caetano Oliveira R; Teixeira P; Silva F; Abrantes C; Figueiredo P; Simões S; Rebelo O; Cipriano MA
Appl Immunohistochem Mol Morphol; 2023 May-Jun 01; 31(5):318-323. PubMed ID: 37093706
[TBL] [Abstract] [Full Text] [Related]
20. Hsa_circ_0073453 modulates IL-8 secretion by GC-MSCs to promote gastric cancer progression by sponging miR-146a-5p.
Wu C; Cao X; Xu J; Wang L; Huang J; Wen J; Wang X; Sang X; Zhu W; Yao Y; Zhou C; Huang F; Wang M
Int Immunopharmacol; 2023 Jun; 119():110121. PubMed ID: 37044033
[TBL] [Abstract] [Full Text] [Related]
[Next]
